In breast cancer, NIC can effectively inhibit the STAT3 activation markers pY705 and pS727 and reduce the STAT3 dimerization capacity, thus significantly reducing the cell proliferation capacity [45]. This evidence concerns the gene STAT3 and breast carcinoma.